Mesoblast (MESO) Current Deferred Revenue (2015)
Mesoblast recorded quarterly Current Deferred Revenue of $15.0 million in Q4 2015, down 33.33% quarter-over-quarter from $22.5 million in Q2 2015.
Mesoblast's Current Deferred Revenue history runs 1 years deep, the most recent figure standing at $15.0 million for Q4 2015.
- In Q4 2015, Current Deferred Revenue changed N/A year-over-year to $15.0 million; the TTM figure through Dec 2015 stood at $15.0 million (changed N/A YoY), while the FY2015 annual figure was $22.5 million, changed N/A from the prior year.
- Current Deferred Revenue came in at $15.0 million for Q4 2015 at Mesoblast, down from $22.5 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $22.5 million in Q2 2015 to a low of $15.0 million in Q4 2015.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Mesoblast | 23.40 Bn | 23.27 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 15.00 Mn |
| Jun 30, 2015 | 22.51 Mn |